Document is current
Any future updates will be listed below
-
Authors
Park, Elizabeth M. https://orcid.org/0000-0002-1670-2299
Chelvanambi, Manoj https://orcid.org/0000-0003-2130-3118
Bhutiani, Neal https://orcid.org/0000-0002-6288-2788
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
Wargo, Jennifer A. https://orcid.org/0000-0003-3438-7576
- License Information
-
More Information
Article History
Received: 8 February 2022
Accepted: 9 March 2022
First Online: 19 April 2022
Competing interests
: J.A.W. is an inventor on a US patent application (PCT/US17/53.717); reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, MedImmune and Bristol-Myers Squibb; serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Micronoma. J.A.W. holds stock options from Micronoma. L.Z. received research contracts from Kaleido, Innovate Pharma and Pilege. G.K. had a research contract with Kaleido. L.Z is and G.K. was among the scientific cofounders of EverImmune, a biotech company devoted to the use of commensal bacteria for the treatment of cancers.
